Company intelligence / Profile preview

BioCaptiva

Edinburgh, Scotland, United Kingdombiocaptiva.com ↗

Ownership: Private
Development stage: Other

Overview

BioCaptiva has developed a patented polymer platform (msX™) and medical devices such as BioCaptor/BioCollector/BioCaptis that can capture up to 100x more cfDNA than standard blood draws. Early studies show potential for improved sensitivity in liquid biopsy for cancer and pleural diseases. First-in-human trials are planned or underway; no published pivotal clinical results yet.

Therapeutic areas: PulmonologyOncology
Modalities: DevicePolymer-based technology (for nucleic acid capture)
Industry: Consumable Medical Devices

Partnerships

University of Edinburgh (spinout origin)NHS Highland & University of the Highlands and Islands (pleural disease study collaboration)Cancer Research Horizons/Cancer Research UK investment partnership

Beyond the preview

Go deeper on BioCaptiva.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioCaptiva.

Explore the full profile